Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

Phase

N/A

Condition

Thyroid Disease

Treatment

Diagnostic DNA Methylation Signature

Clinical Study ID

NCT03676647

18077

NCI-2018-01910

99999

18077

Ages > 19
All Genders

Study Summary

This trial studies how well the diagnostic deoxyribonucleic acid (DNA) methylation signature works in detecting thyroid cancer in patients with thyroid nodules. Using diagnostic testing, such as the diagnostic DNA methylation signature, may be a less invasive way to check for thyroid cancer.

Eligibility Criteria

Inclusion

Inclusion Criteria:

All patients undergoing FNA for thyroid nodule diagnosis.
Any race and ethnicity are eligible for the study.
Patient should have thyroid nodule(s) with indeterminate diagnosis after FNA (Bethesda category of indeterminate FNA [III-V]).

Study Design

Diagnostic DNA Methylation Signature

April 25, 2026

September 25, 2028

Study Description

PRIMARY OBJECTIVES:

I. To validate a novel epigenetic thyroid nodule diagnostic test, diagnostic DNA methylation signature (DDMS) in a retrospective-prospective study with leftover of fine needle aspiration biopsies.

OUTLINE:

Previously collected FNA aspiration specimen samples are analyzed via DDMS assay. Participants undergo FNA aspiration for collection of tissue samples for analysis via DDMS assay.

After completion of study, patients are followed up yearly for 5 years.

Connect with a study center

City of Hope Medical Center
Duarte, California 91010
United States
Site Not Available
City of Hope Medical Center
Duarte 5344147, California 5332921 91010
United States
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.